ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Infinity Licenses Intellikine Compounds

by Rick Mullin
July 19, 2010 | APPEARED IN VOLUME 88, ISSUE 29

Infinity Pharmaceuticals, a small-molecule drug firm in Cambridge, Mass., will obtain development and commercialization rights to Intellikine’s portfolio of inhibitors of the δ and γ isoforms of phosphoinositide-3-kinase (PI3K). They include INK1197, a cancer therapy that is expected to enter the clinic next year. Under the license agreement, Intellikine will receive $13.5 million in initial payments, development payments of up to $25 million, and commercialization payments of up to $450 million.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment